

Aris Liakos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8741917/publications.pdf>

Version: 2024-02-01

35
papers

2,120
citations

393982

19
h-index

395343

33
g-index

35
all docs

35
docs citations

35
times ranked

2599
citing authors

#	ARTICLE	IF	CITATIONS
1	Sodium-glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2013, 159, 262.	2.0	749
2	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 173, 278-286.	2.0	182
3	Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms. <i>Journal of Clinical Epidemiology</i> , 2018, 93, 9-24.	2.4	177
4	Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 984-993.	2.2	176
5	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. <i>Diabetologia</i> , 2022, 65, 1251-1261.	2.9	93
6	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2116-2124.	2.2	79
7	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2255-2263.	2.2	71
8	Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1065-1074.	2.2	61
9	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108737.	1.1	61
10	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 335-345.	2.2	54
11	Accuracy of Magnetic Resonance Imaging in Diagnosis of Liver Iron Overload: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 55-63.e5.	2.4	49
12	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1857-1868.	2.2	44
13	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. <i>Endocrine</i> , 2016, 52, 458-480.	1.1	42
14	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 188-193.	2.2	33
15	A simple plaster for screening for diabetic neuropathy: A diagnostic test accuracy systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 584-592.	1.5	27
16	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015, 6, 61-67.	1.4	26
17	Amiodarone and cardiac arrest: Systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 221, 780-788.	0.8	24
18	Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 517-524.	2.2	23

#	ARTICLE	IF	CITATIONS
19	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , 2018, 31, 572-582.	0.4	19
20	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 106-114.	2.2	19
21	Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. <i>BMJ Open</i> , 2016, 6, e012185.	0.8	18
22	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2395-2401.	2.2	18
23	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 822-831.	2.2	17
24	Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients. <i>Annals of Hematology</i> , 2017, 96, 1937-1944.	0.8	11
25	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. <i>European Journal of Haematology</i> , 2017, 98, 563-568.	1.1	10
26	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108921.	1.1	10
27	Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. <i>Journal of General Internal Medicine</i> , 2020, , 1.	1.3	7
28	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2549-2557.	1.1	6
29	Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis. <i>Endocrine</i> , 2016, 54, 620-633.	1.1	4
30	Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers. <i>Annals of Internal Medicine</i> , 2020, 172, JC27.	2.0	4
31	Some glucose-lowering drugs reduce risk for major adverse cardiac events. <i>Annals of Internal Medicine</i> , 2020, 173, JC9.	2.0	3
32	Canagliflozin for Type 2 diabetes: an up-to-date evidence summary. <i>Diabetes Management</i> , 2015, 5, 119-125.	0.5	2
33	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , 2015, 163, 241.	2.0	1
34	Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1.	0.8	0
35	In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors. <i>Annals of Internal Medicine</i> , 2020, 173, JC70.	2.0	0